Fate Therapeutics (NASDAQ:FATE – Get Rating) and argenx (NASDAQ:ARGX – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.
This table compares Fate Therapeutics and argenx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Fate Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, argenx has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
Insider & Institutional Ownership
Earnings and Valuation
This table compares Fate Therapeutics and argenx’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fate Therapeutics||$96.30 million||5.15||-$281.72 million||($2.42)||-2.08|
|argenx||$445.27 million||50.15||-$709.59 million||($9.29)||-43.17|
Fate Therapeutics has higher earnings, but lower revenue than argenx. argenx is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations for Fate Therapeutics and argenx, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fate Therapeutics currently has a consensus price target of $16.24, suggesting a potential upside of 222.13%. argenx has a consensus price target of $454.24, suggesting a potential upside of 13.26%. Given Fate Therapeutics’ higher possible upside, equities research analysts clearly believe Fate Therapeutics is more favorable than argenx.
argenx beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.